Clinical trials: Double Incontinence
Overactive Bladder
An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).
This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in participants with OAB for up to 52 weeks.
- Trial name
- Empowur (NCT03583372)
- Testing
- Vibegron, Tolterodine Tartrate ER
- Where
- 107 sites in United States
- Volunteers
- 506 people
- Sponsor
- Urovant Sciences GmbH
Overactive Bladder
A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo
A new drug for overactive bladder is compared to placebo to determine if it is safe and effective. The study lasts approximately 12 weeks.
- Trial name
- NCT00350636
- Testing
- Oxybutynin topical gel
- Where
- 63 sites in United States
- Volunteers
- 789 people
- Sponsor
- Watson Pharmaceuticals
Urinary Urge Incontinence
Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge Incontinence
Non-neurogenic urinary urge incontinence (UUI) is a common quality of life disorder that causes people to feel an "urgent" need to urinate.
- Trial name
- NCT01226706
- Testing
- Botulinum Toxins, Type A
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- Saskatchewan Health Authority - Regina Area
Urinary Tract Infections
Nitrofurantoin and Urinary Tract Infections (UTIs)
Urinary tract infection (UTI) is the most common complication after surgery for prolapse or urinary incontinence. UTIs are painful and have the potential to turn into kidney infections.
- Trial name
- APPIC (NCT00678041)
- Testing
- Nitrofurantoin
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Stress Urinary Incontinence
Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence
GTx-024 is an orally bioavailable and tissue-selective nonsteroidal selective androgen receptor modulator (SARM) that has demonstrated androgenic and anabolic activity and is currently being evaluated as a potential treatment for…
- Trial name
- ASTRID (NCT03241342)
- Testing
- GTx 024
- Where
- 62 sites in United States
- Volunteers
- 491 people
- Sponsor
- GTx
Urinary Incontinence, Overactive Bladder
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1
The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® (AbobotulinumtoxinA) doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult…
- Trial name
- CONTENT1 (NCT02660138)
- Testing
- Botulinum toxin type A
- Where
- 81 sites in United States, Canada and 8 more
- Volunteers
- 227 people
- Sponsor
- Ipsen
Urinary Incontinence, Stress
Autologous Muscle Derived Cells Female Stress Urinary Incontinence Clinical Study
This is a clinical trial to study the safety and effectiveness of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR) for the treatment of female stress urinary incontinence (SUI).
- Trial name
- NCT01382602
- Testing
- AMDC-USR
- Where
- 10 sites in Canada, Germany and 1 more
- Volunteers
- 150 people
- Sponsor
- Cook MyoSite
Urinary Incontinence
A Multi-Center Trial of Botox for Severe Urge Urinary Incontinence
The purpose of the study is to determine how effective Botox is in reducing the amount of urine leaked and which dose of Botox is more effective and safe in those who have urinary urge incontinence.
- Trial name
- NCT00345332
- Testing
- Botox
- Where
- 3 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Urge Urinary Incontinence, Urinary Frequency
Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence
The primary objective of the double-blind phase of the study is to compare the effects of two doses of oxybutynin gel to placebo gel.
- Trial name
- NCT00909181
- Testing
- Oxybutynin
- Where
- 55 sites in United States
- Volunteers
- 626 people
- Sponsor
- Antares Pharma Inc.
Overactive Bladder in Parkinson's Disease
Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease
This study will assess the effectiveness of solifenacin succinate (VESIcare) in reducing symptoms of overactive bladder in Parkinson's disease (PD) patients.
- Trial name
- URGE-PD (NCT01018264)
- Testing
- solifenacin succinate (VESIcare)
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- University of South Florida
Urologic Diseases, Urinary Bladder, Overactive
A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.
The purpose of the study was to assess the efficacy, safety and tolerability of mirabegron 50 mg versus (vs) solifenacin 5 mg in the treatment of patients with OAB who were dissatisfied with their treatment due to lack of…
- Conditions
- Urologic Diseases, Urinary Bladder, Overactive, Urinary Bladder Diseases
- Trial name
- BEYOND (NCT01638000)
- Testing
- Mirabegron, Solifenacin succinate
- Where
- 217 sites in Armenia, Austria and 31 more
- Volunteers
- 1,887 people
- Sponsor
- Astellas Pharma Europe Ltd.
Urinary Incontinence
Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence
The purpose of this study is to determine if a new drug treatment is effective for the treatment of symptoms of urinary incontinence.
- Trial name
- NCT01340066
- Testing
- UISH001
- Where
- 3 sites in United States
- Volunteers
- 94 people
- Sponsor
- Beech Tree Labs, Inc.
Urinary Bladder, Overactive
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.
- Trial name
- SCORPIO (NCT00689104)
- Testing
- Mirabegron, Tolterodine
- Where
- 218 sites in Australia, Austria and 28 more
- Volunteers
- 2,336 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder
To compare the effect of tolterodine ER 4 mg to placebo on patient reported outcomes in subjects with overactive bladder after 1, 4, and 12 weeks of treatment using an innovative web-based trial design
- Trial name
- REMOTE (NCT01302938)
- Testing
- Tolterodine ER
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Stress Urinary Incontinence
Autologous Muscle Derived Cells for Female Urinary Sphincter Repair
This randomized, double-blind, placebo-controlled, multicenter, confirmatory study will evaluate the efficacy and safety of Cook MyoSite Incorporated Autologous Muscle-Derived Cells (generic name Iltamiocel) compared to a placebo…
- Trial name
- NCT01893138
- Testing
- Iltamiocel
- Where
- 29 sites in United States, Belgium and 1 more
- Volunteers
- 311 people
- Sponsor
- Cook MyoSite
Stress Urinary Incontinence
Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients
The hypothesis under evaluation is that fesotorodine may provide clinical benefit in the treatment of the condition of stress urinary incontinence
- Trial name
- NCT01042236
- Testing
- Fesoterodine
- Where
- Denmark
- Volunteers
- 22 people
- Sponsor
- Pfizer
Dual Incontinence, Fecal Incontinence
Sacral Neuromodulation in Dual Incontinence: Ultrasound and Afferent Nerve Sensation Assessment
Women with Dual Incontinence (DI) (both Urinary Incontinence (UI) and Fecal Incontinence (FI)) often have more bothersome symptoms, quality of life impact, and sexual dysfunction than those with just UI or FI.
- Conditions
- Dual Incontinence, Fecal Incontinence, Urinary Incontinence, Sacral Neuromodulation
- Trial name
- SaNDI (NCT02357784)
- Testing
- Neurometer
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Northwestern University
Overactive Bladder, Urinary Urge Incontinence
Reduction of Bladder Injection Pain With Belladonna Opiate Suppository
The purpose of this study is to test whether using belladonna \& opiate suppositories (B\&Os) can improve patient discomfort during Onabotulinumtoxin A (BoNT) injection into the bladder for treatment of overactive bladder…
- Conditions
- Overactive Bladder, Urinary Urge Incontinence, Urinary Bladder, Neurogenic, Painful Bladder Syndrome
- Trial name
- ROBIN (NCT02600715)
- Testing
- Onabotulinumtoxin A (BoNT), belladonna, Morphine
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Edgar LeClaire, MD
Urologic Diseases, Urinary Bladder Diseases
A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder
The purpose of this study is to examine how well two medicines in combination (solifenacin succinate and mirabegron) work in the treatment of bladder problems over a 12-week period.
- Conditions
- Urologic Diseases, Urinary Bladder Diseases, Urological Manifestations, Signs and Symptoms
- Trial name
- Symphony (NCT01340027)
- Testing
- Mirabegron, Solifenacin succinate
- Where
- 133 sites in Belarus, Belgium and 18 more
- Volunteers
- 1,307 people
- Sponsor
- Astellas Pharma Europe B.V.
Urinary Incontinence
DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence
This study will explore the safety, tolerability and efficacy of litoxetine in men and women who suffer from urinary incontinence
- Trial name
- NCT03397771
- Testing
- Litoxetine
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Ixaltis SA